China Shineway Pharmaceutical Group Limited
CSWYFOTCHealthcare● Active
$1.08
+$0.08(+7.57%)
Market Cap$815832000
P/E Ratio—
52W High$1.08
52W Low$0.9253
China Shineway Pharmaceutical Group Limited (CSWYF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSWYF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.14B | $3.78B | $32.00B | $4.03B | $3.17B |
| Cost of Revenue | $0.87B | $0.95B | $7.95B | $1.03B | $0.80B |
| Gross Profit | $2.27B | $2.83B | $24.04B | $3.00B | $2.37B |
| Gross Margin %(computed) | 72.28% | 74.95% | 75.15% | 74.38% | 74.77% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.10B | $0.78B | $0.12B | $0.11B |
| G&A Expenses | $0.28B | $0.29B | $2.31B | $1.92B | $1.63B |
| Total Operating Expenses | $1.55B | $1.99B | $17.13B | $2.27B | $1.87B |
| Operating Income | $0.72B | $0.84B | $6.91B | $0.73B | $0.53B |
| Operating Margin %(computed) | 22.89% | 22.30% | 21.60% | 18.06% | 16.58% |
| Interest Income | $0.22B | $0.18B | $0.67B | $0.09B | $0.10B |
| Interest Expense | $0.01B | $0.01B | $0.02B | $0.00B | $0.00B |
| Income Before Tax | $1.27B | $1.15B | $1.24B | $0.94B | $0.71B |
| Income Tax Expense | $0.32B | $0.31B | $0.27B | $0.20B | $0.16B |
| Net Income | $0.95B | $0.84B | $0.97B | $0.74B | $0.56B |
| Net Margin %(computed) | 30.30% | 22.24% | 3.04% | 18.30% | 17.55% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.26 | $1.11 | $1.28 | $0.96 | $0.74 |
| Wtd Avg Shares | 0.76B | 0.76B | 0.76B | 0.76B | 0.76B |
| EBITDA | $1.35B | $1.22B | $8.87B | $1.00B | $0.77B |
| EBITDA Margin %(computed) | 42.92% | 32.31% | 27.71% | 24.71% | 24.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more China Shineway Pharmaceutical Group Limited data
About China Shineway Pharmaceutical Group Limited (CSWYF) Income Statement
China Shineway Pharmaceutical Group Limited (CSWYF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSWYF reported revenue of $3.14B, gross profit of $2.27B (gross margin 72.28%), and net income of $0.95B — a net profit margin of 30.30%.
Frequently asked questions
CSWYF · 4 questionsChina Shineway Pharmaceutical Group Limited (CSWYF) reported revenue of $3.14B for 2025, down 17.0% year-over-year.
CSWYF revenueCSWYF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09